XL-888

Generic Name: XL-888

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₇N_₅O_₃

CAS Number: 1149705-71-4

Unique Ingredient Identifier: 7M346920EV

Background: XL888 has been used in trials studying the treatment of Cancer and Melanoma.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Phase 1

Completed

Conditions: Stage IVB Colorectal Cancer
Stage IVB Pancreatic Cancer
Unresectable Pancreatic Carcinoma
Colorectal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Recurrent Colorectal Carcinoma
Recurrent Pancreatic Carcinoma
Stage III Colorectal Cancer
Stage III Pancreatic Cancer
Stage IIIA Colorectal Cancer

Interventions: Drug: XL888
Biological: Pembrolizumab

First Posted Date: 2017-03-30

Last Posted Date: 2023-12-05

Lead Sponsor: Emory University

Target Recruit Count: 49

Registration Number: NCT03095781

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma
Skin Cancer

Interventions: Drug: XL888
Drug: Vemurafenib
Drug: Cobimetinib

First Posted Date: 2016-03-29

Last Posted Date: 2024-11-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 26

Registration Number: NCT02721459

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: XL888
Drug: Vemurafenib

First Posted Date: 2012-08-06

Last Posted Date: 2023-01-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT01657591

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: XL888

First Posted Date: 2008-11-24

Last Posted Date: 2015-08-21

Lead Sponsor: Exelixis

Target Recruit Count: 33

Registration Number: NCT00796484

Locations: 🇺🇸
Hospital of the University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy